TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Personalized rTMS for Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged from 18 to 65 Y~* Affiliated to the health insurance~* Having signed an informed consent~* Suffering from major depression according to the DSM5~* Unresponsive or incomplete remission after at least one trial of antidepressant (\> 6 weeks at efficient dose or side effects)~* Treatment stable for \> 6 weeks~Exclusion Criteria:~* Contraindication for MRI, rTMS or tDCS: non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump clip or vascular stent, heart valve or ventricular shunt, seizure disorders, skin pathology in the region of tDCS electrode placement.~* Pregnancy~* Severe and non-stabilized somatic pathology~* Patients deprived of liberty or hospitalized without their consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Individualized rTMS (transcranial magnetic stimulation) (Type: EXPERIMENTAL): The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks.
- Classical rTMS (transcranial magnetic stimulation) (Type: ACTIVE_COMPARATOR): rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
- Classical tDCS (transcranial direct current stimulation) (Type: ACTIVE_COMPARATOR): tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Poorly controlled asthma;~* Average use of over 2 puffs of albuterol per day in the previous 7 days OR Having symptoms of asthma on 5 of the last 7 days OR Awakening at night due to asthma at least once in the previous 7 days OR Having been treated with a course of oral or intravenous steroids at least once in the last 3 months.~Exclusion Criteria:~* Subjects receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for rhinitis;~* Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, oral or intranasal anticholinergics;~* History and/or presence of any non-asthmatic acute or chronic lung disease, including but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis or cystic fibrosis;~* History and/or presence of any clinically significant cardiovascular disease, clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal cell carcinoma, and significant psychiatric disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Qvar (Type: EXPERIMENTAL): Qvar 160 mcg twice daily
- Flovent Diskus (Type: ACTIVE_COMPARATOR): Flovent Diskus 200 mcg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Studying Survivorship Care Plans in Head and Neck Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed treatment for a head or neck cancer at Duke Cancer Center within 4 months of consent OR~* Will complete treatment for a head and neck cancer at Duke Cancer Center within 3 weeks of consent AND~* Able to read and understand English~* Capable of giving informed consent~* Are at least age 18.~Exclusion Criteria:~* incompetent for interview (documented diagnosis of active psychosis or dementia) or unable to provide informed consent as assessed by the interviewer; or too sick to participate, as judged by a member of the research team

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No SCP Control (Type: NO_INTERVENTION): Patients returning for early follow-up who did not receive SCP.
- SOC SCP Control (Type: NO_INTERVENTION): Patients returning for early follow-up who received a standard of care SCP.
- eSCP Intervention (Type: EXPERIMENTAL): Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent GEP NET Ki 67 ≤ 10 %~* Histologically or cytologically confirmed GEP NET~* Appearance of carcinoid syndrome maximum 6 months before the inclusion~* Evaluable or measurable disease (RECIST 1.1) WHO ECOG performance status 0-2~* Positive somatostatin receptor scintigraphy~* \>18 years~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Uncontrolled concurrent disease which prevents the adequate management and follow-up of the NET.~* Previous malignancy in the last past 3 years except malignancies estimated as completely cured.~* Current pregnancy or breast feeding~* Concomitant anti-tumoral treatment, except external beam radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Activated vitamin D administration~* On chronic hemodialysis for ≥ 6 months~* Use of a synthetic biocompatible dialysis membrane~* 25-hydroxyvitamin D levels \< 30 ng/mL~* Corrected serum calcium \< 10.2 mg/dL~* Serum phosphate \< 7 mg/dL~* Iron replete (Ferritin \> 200 ng/mL and transferrin saturation \> 20%)~Exclusion Criteria:~* Current participation in any other investigational drug trial~* Vitamin D deficiency due to a heredity disorder~* Liver disease or failure~* Current or past treatment with ergocalciferol or cholecalciferol ≥ 2000 IU per day (within the past 6 months)~* Treatment with calcimimetics or bisphosphonates within the last 3 months~* Treatment with anti-epileptics or other medications that can effect vitamin D metabolism~* Malnutrition (serum albumin \< 2.5 mg/dL)~* Pregnancy, positive pregnancy test or breastfeeding~* Malignancy or other significant inflammatory disease~* HIV/AIDS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ergocalciferol (Type: EXPERIMENTAL): Ergocalciferol 50,000 IU by mouth once weekly for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth once weekly for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2 Different Positional Therapies for Positional Obstructive Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients able to give writtent consent with a de novo diagnosis of positional sleep apnoea according to a polysomnograph.~Exclusion Criteria:~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Positional pillow followed by vibrating belt (Type: EXPERIMENTAL): 26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
- Vibrating belt followed by positional pillow (Type: EXPERIMENTAL): 26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Transcranial Direct Current Stimulation (tDCS).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-40~2. Within 2-weeks s/p acute grade 1 or 2 ankle inversion sprain~Exclusion Criteria:~1. Self-Reported Pregnancy~2. Being treated for and on medication for a mental health diagnosis~3. Concussion or non-lateral ankle sprain lower extremity injuries within the past 6 months~4. Open wound or dermatologic lesion on the head or region of application~5. Active implantable medical devices such as cochlear implants or cardiac pacemakers, or with metal implants in the head (excluding standard orthodontic braces, fillings, etc.).~6. Epilepsy or history of seizures~7. Participants who are not fluent in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Transcranial Direct Current Stimulation plus Physical Therapy (Type: EXPERIMENTAL): Participants in the experimental group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute application of tDCS during each treatment session via the Halo Sport (Halo Neuroscience, San Francisco, CA) headset. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
- Sham Transcranial Direct Current Stimulation plus Physical Therapy (Type: SHAM_COMPARATOR): Participants in the sham control group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute sham tDCS treatment, where the patient is wearing the tDCS headset, but stimulation is only applied for 30 seconds of the 20-minute period. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in Refractory Convulsive Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis and clinical EEGrafica of refractory convulsive status epilepticus~* Refractoriness of the drug I and II line~* Written informed consent from parents or legal guardian.~* Administration of rating scales in the risk of mortality (PIM III) and severity of SE (stess, status epilepticusseverity score) to be performed prior to randomization.~Exclusion Criteria:~* contraindications to the use of the medication/s in the study.~* pregnant or suspected pregnant.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- ketamine up to 100 mcg/kg/min (Type: EXPERIMENTAL): Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
- midazolam & thiopental & propofol (Type: ACTIVE_COMPARATOR): Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stroke Patients Receiving Chiropractic Care Post-rehabilitation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post stroke rehabilitation~Exclusion Criteria:~* Not experienced sub-arachnoid bleeding within the last 4 weeks, fractures or trauma to the skull, pregnancy, or progressive RA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chiropractic care for Ischemic Stroke Patients (Type: EXPERIMENTAL): 12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
- Chiropractic care for Hemorrhagic Stroke Patients (Type: EXPERIMENTAL): 12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntary signature of the Informed Consent~2. Axial low back pain for a minimum of 3 months~3. Male or female ages 18-75~4. Recent MRI (within last 6 months) consistent Kader grade 2 or 3 multifidus atrophy at 1 or 2 levels~5. Is independent, ambulatory, and can comply with all post-operative evaluations and visits~Exclusion Criteria:~1. Mild multifidus atrophy Kader grade 1~2. Multifidus atrophy at more than 2 levels~3. Symptomatic spinal stenosis (e.g. pseudoclaudication with moderate or severe MRI findings of stenosis)~4. Radicular symptoms (e.g. lower extremity radiating numbness, tingling, paresthesia, etc)~5. Fracture, previous spine surgery, neuromuscular disease of the trunk, malignancy, infection, or pregnancy~6. Radiofrequency ablation within the previous 12 months~7. Corticosteroid injection (epidural or facet) within the past 3 months~8. Contraindications for MRI~9. Condition represents a worker's compensation case~10. Currently involved in a health-related litigation procedure~11. Bleeding disorders~12. Allergy or intolerance to study medication~13. Use of chronic opioid~14. Documented history of drug abuse within six months of treatment~15. Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PPP treatment (Type: EXPERIMENTAL): Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
- PRP treatment (Type: EXPERIMENTAL): 5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
- PRP and PL Combo treatment (Type: EXPERIMENTAL): 5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients who progress after 1st line therapy with FOLFOX/AVASTIN~* Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit),renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~* Previous treatments with all effective drugs for metastatic colorectal cancer (CPT-11, LOHP, 5-FU/XELODA, Erbitux, Avastin)~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias)~* History of myocardial infarction or stroke within 6 months~* Clinically significant peripheral vascular disease~* History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0~* Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1~* Presence of central nervous system or brain metastases~* Evidence of bleeding diathesis or coagulopathy~* Blood pressure \> 150/100 mmHg~* Pregnant or lactating woman~* Life expectancy \< 3 months~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow~* Metastatic infiltration of the liver \>50%~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy~* Active infection requiring antibiotics on Day 1~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer~* Psychiatric illness or social situation that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): LoHP/AIO/Avastin-\>CPT-11/AIO/Erbitux

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Intensive Nutritional Supplement in Patient With Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1 st onset stroke patient~* MRI confirms his/her stroke~* more than 2.5% weight los within 2 weeks~* initial serum albumin \< 35 g/l~* BMI \< 18.5~* more than MMSE 10~* medically stable~Exclusion Criteria:~* recurrent stroke patient~* malabsorption patient~* terminal cancer

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- high protein supplement (Type: EXPERIMENTAL): high protein supplement given
- Control (Type: NO_INTERVENTION): no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy